Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Current Leases (2019 - 2025)

Historic Current Leases for Viking Therapeutics (VKTX) over the last 7 years, with Q3 2025 value amounting to $437000.0.

  • Viking Therapeutics' Current Leases fell 895.83% to $437000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $437000.0, marking a year-over-year decrease of 895.83%. This contributed to the annual value of $489000.0 for FY2024, which is 5092.59% up from last year.
  • Viking Therapeutics' Current Leases amounted to $437000.0 in Q3 2025, which was down 895.83% from $468000.0 recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Current Leases peaked at $498000.0 during Q1 2025, and registered a low of $29000.0 during Q4 2021.
  • Over the past 5 years, Viking Therapeutics' median Current Leases value was $314000.0 (recorded in 2023), while the average stood at $311210.5.
  • Per our database at Business Quant, Viking Therapeutics' Current Leases tumbled by 9121.21% in 2021 and then soared by 94827.59% in 2022.
  • Viking Therapeutics' Current Leases (Quarter) stood at $29000.0 in 2021, then soared by 948.28% to $304000.0 in 2022, then increased by 6.58% to $324000.0 in 2023, then surged by 50.93% to $489000.0 in 2024, then decreased by 10.63% to $437000.0 in 2025.
  • Its Current Leases was $437000.0 in Q3 2025, compared to $468000.0 in Q2 2025 and $498000.0 in Q1 2025.